OrbiMed’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

OrbiMed’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-170,769	Closed	-$25.8K	–	139
2022 Q3	$25.8K	Sell	170,769 -548,265	-76%	-$81.3M	0.48%	62
2022 Q2	$105K	Hold	719,034	–	–	1.9%	17
2022 Q1	$85.3M	Buy	+719,034	New	+$89.7M	1.38%	24

Other funds holding BHVN

LIP

Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

OrbiMed's BHVN Position: Q4 2022 in Review

OrbiMed sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 170,769 shares — an estimated $25.8K sold.

OrbiMed first reported a position in BHVN in Q1 2022 and held it in 3 quarters. The position peaked at $85.3M in Q1 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

OrbiMed reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 170,769 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $25.8K.
OrbiMed first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022 and held it in 3 quarters.
OrbiMed's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $85.3M in Q1 2022.
7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.